Tokyo Tape
Sign in
← Kirin Holdings

Annual report

2503.TEDINET S100VH7L
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 148
MetricValuePeriodScopeSource row
Revenue¥2.34T2024-01-01 → 2024-12-31Cons.Revenue IFRS
Revenue¥2.13T2023-01-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥1.99T2022-01-01 → 2022-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.82T2021-01-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.85T2020-01-01 → 2020-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥125.3bn2024-01-01 → 2024-12-31Cons.Operating profit loss IFRS
Operating income¥150.3bn2023-01-01 → 2023-12-31Cons.Operating profit loss IFRS
Profit before tax¥139.7bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS
Profit before tax¥197.0bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥191.4bn2022-01-01 → 2022-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥99.6bn2021-01-01 → 2021-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥124.5bn2020-01-01 → 2020-12-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥58.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥111.0bn2022-01-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥59.8bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥71.9bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥85.8bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS
Net income¥150.4bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS
Total assets¥3.35Tat 2024-12-31Cons.Assets IFRS
Total assets¥2.87Tat 2023-12-31Cons.Assets IFRS
Total assets¥2.54Tat 2022-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.47Tat 2021-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.46Tat 2020-12-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥1.82Tat 2024-12-31Cons.Liabilities IFRS
Total liabilities¥1.44Tat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥1.53Tat 2024-12-31Cons.Equity IFRS
Net assets / equity¥1.43Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.25Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥1.18Tat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.13Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥980.0bnat 2022-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥894.2bnat 2021-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥838.6bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥118.6bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥131.4bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.1bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥149.5bnat 2021-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥161.7bnat 2020-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥242.8bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥203.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥135.6bn2022-01-01 → 2022-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥219.3bn2021-01-01 → 2021-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥164.8bn2020-01-01 → 2020-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥329.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥226.1bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥10.4bn2022-01-01 → 2022-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥56.4bn2021-01-01 → 2021-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥116.0bn2020-01-01 → 2020-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow¥58.1bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥35.9bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥167.8bn2022-01-01 → 2022-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥180.5bn2021-01-01 → 2021-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥52.5bn2020-01-01 → 2020-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥71.872024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥139.162023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥135.082022-01-01 → 2022-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥71.732021-01-01 → 2021-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥85.572020-01-01 → 2020-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥71.862024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥139.152023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥135.072022-01-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥71.72021-01-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥85.542020-01-01 → 2020-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥1,458.68at 2024-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,398.47at 2023-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,210.16at 2022-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,072.69at 2021-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,005.96at 2020-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio35.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio38.5%at 2022-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.2%at 2021-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio34.1%at 2020-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE5.0%2024-01-01 → 2024-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE10.7%2023-01-01 → 2023-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE11.8%2022-01-01 → 2022-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE6.9%2021-01-01 → 2021-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE8.2%2020-01-01 → 2020-12-31dCons.Rate of return on equity IFRS (5-year summary)
Employees31,934at 2024-12-31Cons.Number of employees
Revenue¥194.6bn2024-01-01 → 2024-12-31StandaloneOperating revenue1
Revenue¥139.0bn2023-01-01 → 2023-12-31StandaloneOperating revenue1
Revenue¥152.8bn2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥139.5bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥138.8bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income¥114.5bn2024-01-01 → 2024-12-31StandaloneOperating income
Operating income¥64.4bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income¥60.4bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income¥62.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥76.9bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥73.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥72.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥332.2bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax¥77.2bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income−¥344.9bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income¥70.4bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥48.7bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income¥77.3bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥79.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.85Tat 2024-12-31StandaloneAssets
Total assets¥2.28Tat 2023-12-31StandaloneAssets
Total assets¥1.90Tat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.00Tat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.97Tat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥1.29Tat 2024-12-31StandaloneLiabilities
Total liabilities¥1.32Tat 2023-12-31StandaloneLiabilities
Net assets / equity¥561.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥964.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥951.1bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥1.01Tat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥987.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥12.2bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥20.2bnat 2023-12-31StandaloneCash and deposits
EPS (basic)¥-425.842024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥86.912023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥59.242022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥92.672021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥94.372020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥712024-01-01 → 2024-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥712023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥692022-01-01 → 2022-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥652021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥652020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥693.7at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,190.61at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,174.47at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,208.06at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,184.06at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio30.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio42.3%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio50.1%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio50.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio50.1%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE-45.2%2024-01-01 → 2024-12-31StandaloneRate of return on equity (5-year summary)
ROE7.3%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE5.0%2022-01-01 → 2022-12-31dStandaloneRate of return on equity (5-year summary)
ROE7.8%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE7.8%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued914,000,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,067at 2024-12-31StandaloneNumber of employees
Employees977at 2023-12-31StandaloneNumber of employees
Employees914at 2022-12-31dStandaloneNumber of employees
Employees1,156at 2021-12-31dStandaloneNumber of employees
Employees1,117at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 75
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2024-01-01 → 2024-12-31¥7.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2024-12-312113 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-12-31¥97.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-12-31¥21.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-12-31¥76.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-12-31¥362.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-12-31¥30m
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥10.4bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-12-31−¥86.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-12-31−¥86.4bn
Reconciling Itemsreconcilingsegment assetsat 2024-12-31−¥478.8bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥58.0bn
Alcoholic Beveragesreportable segmentcapex2024-01-01 → 2024-12-31¥39.0bn
Alcoholic Beveragesreportable segmentemployeesat 2024-12-318925 pure
Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-12-31¥1.08T
Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-12-31¥1.08T
Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥2.3bn
Alcoholic Beveragesreportable segmentsegment assetsat 2024-12-31¥1.37T
Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-12-31¥124.0bn
Health Sciencereportable segmentcapex2024-01-01 → 2024-12-31¥6.7bn
Health Sciencereportable segmentemployeesat 2024-12-315954 pure
Health Sciencereportable segmentrevenue2024-01-01 → 2024-12-31¥179.5bn
Health Sciencereportable segmentrevenue external2024-01-01 → 2024-12-31¥175.3bn
Health Sciencereportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥4.2bn
Health Sciencereportable segmentsegment assetsat 2024-12-31¥764.1bn
Health Sciencereportable segmentsegment profit2024-01-01 → 2024-12-31−¥10.9bn
Non Alcoholic Beveragesreportable segmentcapex2024-01-01 → 2024-12-31¥20.9bn
Non Alcoholic Beveragesreportable segmentemployeesat 2024-12-317887 pure
Non Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-12-31¥567.8bn
Non Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-12-31¥564.9bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥3.0bn
Non Alcoholic Beveragesreportable segmentsegment assetsat 2024-12-31¥326.4bn
Non Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-12-31¥64.0bn
Pharmaceuticalsreportable segmentcapex2024-01-01 → 2024-12-31¥109.5bn
Pharmaceuticalsreportable segmentemployeesat 2024-12-315669 pure
Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-12-31¥495.6bn
Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-12-31¥495.3bn
Pharmaceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥264m
Pharmaceuticalsreportable segmentsegment assetsat 2024-12-31¥1.01T
Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-12-31¥91.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2023-01-01 → 2023-12-31¥2.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-12-31¥94.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-12-31¥27.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-12-31¥66.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-12-31¥510.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-12-31−¥60m
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥10.3bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-12-31−¥76.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-12-31−¥76.4bn
Reconciling Itemsreconcilingsegment assetsat 2023-12-31−¥719.8bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥54.2bn
Alcoholic Beveragesreportable segmentcapex2023-01-01 → 2023-12-31¥39.1bn
Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-12-31¥1.05T
Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-12-31¥1.05T
Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥2.3bn
Alcoholic Beveragesreportable segmentsegment assetsat 2023-12-31¥1.35T
Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-12-31¥119.9bn
Health Sciencereportable segmentcapex2023-01-01 → 2023-12-31¥10.1bn
Health Sciencereportable segmentrevenue2023-01-01 → 2023-12-31¥108.0bn
Health Sciencereportable segmentrevenue external2023-01-01 → 2023-12-31¥103.4bn
Health Sciencereportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥4.7bn
Health Sciencereportable segmentsegment assetsat 2023-12-31¥473.7bn
Health Sciencereportable segmentsegment profit2023-01-01 → 2023-12-31−¥12.5bn
Non Alcoholic Beveragesreportable segmentcapex2023-01-01 → 2023-12-31¥24.2bn
Non Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-12-31¥518.9bn
Non Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-12-31¥516.2bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥2.8bn
Non Alcoholic Beveragesreportable segmentsegment assetsat 2023-12-31¥287.4bn
Non Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-12-31¥52.4bn
Pharmaceuticalsreportable segmentcapex2023-01-01 → 2023-12-31¥33.3bn
Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-12-31¥442.2bn
Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-12-31¥441.9bn
Pharmaceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥351m
Pharmaceuticalsreportable segmentsegment assetsat 2023-12-31¥971.4bn
Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-12-31¥96.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 2,393
ItemContextValueUnit
Finance costs IFRSCurrentYearDuration17994000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYearDuration37035000000JPY
Impairment loss on equity accounted investees IFRSCurrentYearDuration19255000000JPY
Profit loss before tax IFRSCurrentYearDuration139721000000JPY
Assets IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember1367470000000JPY
Assets IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember326366000000JPY
Assets IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember1012722000000JPY
Assets IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember764058000000JPY
Assets IFRSCurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember362385000000JPY
Assets IFRSCurrentYearInstant_ReconcilingItemsMember-478841000000JPY
Assets IFRSCurrentYearInstant3354159000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember36070000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember12778000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember24780000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember8937000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember3753000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_ReconcilingItemsMember9383000000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration95702000000JPY
Impairment losses pl IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember3902000000JPY
Impairment losses pl IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember－JPY
Impairment losses pl IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember2060000000JPY
Impairment losses pl IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember7427000000JPY
Impairment losses pl IFRSCurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember－JPY
Impairment losses pl IFRSCurrentYearDuration_ReconcilingItemsMember－JPY
Impairment losses pl IFRSCurrentYearDuration13389000000JPY
Investments accounted for using equity method IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember213065000000JPY
Investments accounted for using equity method IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember－JPY
Investments accounted for using equity method IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember3139000000JPY
Investments accounted for using equity method IFRSCurrentYearInstant_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember－JPY
Investments accounted for using equity method IFRSCurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember－JPY
Investments accounted for using equity method IFRSCurrentYearInstant_ReconcilingItemsMember－JPY
Investments accounted for using equity method IFRSCurrentYearInstant216205000000JPY
Capital expenditures IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember39024000000JPY
Capital expenditures IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember20897000000JPY
Capital expenditures IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember109474000000JPY
Capital expenditures IFRSCurrentYearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember6683000000JPY
Capital expenditures IFRSCurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember7172000000JPY
Capital expenditures IFRSCurrentYearDuration_ReconcilingItemsMember10358000000JPY
Capital expenditures IFRSCurrentYearDuration193607000000JPY
Buildings and structures IFRSPrior1YearInstant223553000000JPY
Machinery and vehicles IFRSPrior1YearInstant192534000000JPY
Tools furniture and fixtures IFRSPrior1YearInstant47807000000JPY
Land IFRSPrior1YearInstant85723000000JPY
Construction in progress IFRSPrior1YearInstant43311000000JPY
Property plant and equipment IFRSPrior1YearInstant592928000000JPY
Buildings and structures IFRSCurrentYearInstant254594000000JPY
Machinery and vehicles IFRSCurrentYearInstant203092000000JPY
Tools furniture and fixtures IFRSCurrentYearInstant50639000000JPY
Land IFRSCurrentYearInstant114886000000JPY
Construction in progress IFRSCurrentYearInstant50818000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass